Developer docs
API playgroundTry for free, no card

Search company profiles

Mestastop Solutions

Full company profile

uuid0003dir

Namestring
Mestastop Solutions
Websiteurl
mestastop.com
Company typeenum
Private
Founded yearint
2018
Descriptiontext

Mestastop Solutions is a Bengaluru-based, privately held biotech startup founded in 2018 that focuses on cancer metastasis — the spread of cancer cells from a primary tumor to secondary organs, which is a leading cause of cancer-related death. The company develops proprietary in vitro, in vivo, and patient ex-vivo platforms to address both metastasis drug discovery and predictive diagnostics. Its core work centers on identifying and blocking cancer cells capable of spreading, using two repurposed drugs to target metastasis in colorectal cancer patients in a planned Phase II clinical trial.

Mestastop's technology stack comprises three integrated proprietary tools — METAssay, METSCAN, and METVivo — that collectively recreate and analyze a 30-step metastasis process to surface specific cells capable of disseminating to secondary organs. The company has secured regulatory approval to launch a Phase II trial enrolling at least 60 post-surgery colorectal cancer patients in a two-year treatment regimen, with results expected in approximately three years. Cumulative disclosed funding across three rounds (2020–2023) is approximately $714,000, with backers including Mumbai Angels, IIMA Ventures, IKP Knowledge Park, 92 Angels, and Malpani Ventures. The company is co-founded by Debabani Roy Chowdhury and Arnab Roy Chowdhury.

The business model is pre-commercial: Mestastop is a clinical-stage biotech with no disclosed pricing, no paying customers, and no product revenue. Its go-to-market motion is enterprise-field-sales and regulatory-driven, dependent on clinical trial execution, future pharma partnerships, or licensing of its repurposed-drug assets and diagnostic platforms. Geographic footprint is currently limited to Bengaluru, India, with 11–50 employees and no subsidiaries or institutional parent identified in the data.

Short descriptiontext

Mestastop Solutions is a Bengaluru-based clinical-stage biotech that uses three proprietary platforms (METAssay, METSCAN, METVivo) to identify and block metastasis-causing cancer cells, advancing two repurposed drugs into a Phase II colorectal cancer trial.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersMarlton, United States
HQ citystring
Marlton
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
cancer metastasis research, drug discovery platforms, predictive diagnostics, in vitro assays, clinical trials
Industry3 codes
PRIMARYHLAAALAE
Oncology Diagnostics (tumor profiling, MRD, liquid biopsy)
SECONDARYHLAIALAE
Clinical Development (Phase I–III Trial Design & Execution)
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Research and Development
SECONDARYHLAKAFAB
Medical Oncology
NAICS code2 codes
  • In-Vitro Diagnostic Substance Manufacturing325413
  • Medical and Diagnostic Laboratories62151
SIC code2 codes
  • In Vitro & In Vivo Diagnostic Substances2835
  • Services-Commercial Physical & Biological Research8731
Product category
Oncology Drug Discovery
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Cost components5 values
Personnel, Technology or R&D, Operations, Marketing or Sales, Others
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

Mestastop Solutions develops proprietary in vitro, in vivo, and patient ex-vivo platforms that recreate and analyze the 30-step metastasis process to identify and block cancer cells capable of spreading to secondary organs. The company is preparing a Phase II clinical trial with two repurposed drugs targeting metastasis in post-surgery colorectal cancer patients, with plans to enroll at least 60 patients in a two-year treatment regimen.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

Mestastop Solutions offers a unified platform comprised of three integrated proprietary tools — METAssay, METSCAN, and METVivo — that collectively recreate and analyze the 30-step metastasis process to identify and block specific cancer cells capable of spreading to secondary organs. The company is developing two repurposed drugs for a Phase II clinical trial targeting metastasis in colorectal cancer patients.

Product and service3 records
1METAssay
Description

One of three integrated proprietary tools that recreates and analyzes the metastasis process to identify cancer cells capable of spreading to secondary organs; part of Mestastop's platform for metastasis drug discovery and predictive diagnostics.

2METSCAN
Categoryproprietary platform
Description

One of three integrated proprietary tools that recreates and analyzes the metastasis process to identify cancer cells capable of spreading to secondary organs; part of Mestastop's platform for metastasis drug discovery and predictive diagnostics.

3METVivo
Categoryproprietary platform
Description

One of three integrated proprietary tools that recreates and analyzes the metastasis process to identify cancer cells capable of spreading to secondary organs; part of Mestastop's platform for metastasis drug discovery and predictive diagnostics.

Scale indicator3 records

Each record includes

Type, Value, Description, Source

Recent move5 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Precision oncology biotech using proprietary platforms to discover and develop antibody and small-molecule therapeutics against high-value cancer targets. Comparable in platform-driven discovery approach and clinical-stage positioning.

TypeBroad incumbent
Description

Established oncology precision medicine company offering liquid biopsy and molecular diagnostics to identify and monitor cancer, including metastatic disease. A broad incumbent in cancer diagnostics that validates the market Mestastop's predictive diagnostics platform targets.

3Tempus AI
TypeBroad incumbent
Description

AI-enabled precision medicine company with extensive oncology data, diagnostics, and drug-discovery capabilities. A broad incumbent in oncology data and diagnostics that contextualizes Mestastop's platform approach at scale.

4SEngine Precision Medicine
TypeEmerging player
Description

Functional diagnostics company that uses patient-derived tumor cells to test drug sensitivity and guide oncology treatment selection. Comparable in patient ex-vivo testing methodology and cancer-drug matching approach.

TypeDirect peer
Description

AI-driven oncology drug development company with a focus on repurposed and accelerated drug development programs, including in metastatic indications. Highly comparable in its use of repurposed drugs and platform-enabled oncology development.

TypeBroad incumbent
Description

Major oncology molecular diagnostics company (a Roche subsidiary) providing comprehensive genomic profiling of tumors to inform cancer treatment. A broad incumbent whose cancer-profiling capabilities overlap with Mestastop's predictive diagnostics positioning.

7Notable Labs
TypeEmerging player
Description

Functional precision medicine platform that tests cancer drugs (including repurposed drugs) against patient-derived cancer cells to predict response. Comparable in combining ex-vivo patient-cell testing with drug repurposing in oncology.

8Repurpose.AI
TypeEmerging player
Description

AI-driven drug repurposing platform with applications across oncology. Comparable through the shared repurposed-drug development model targeting cancer indications.

TypeDirect peer
Description

AI- and structure-based drug discovery company focused on oncology, using computational platforms to identify novel candidates. Comparable in platform-driven oncology drug discovery, although at a more advanced clinical stage.

10Inzen Therapeutics
TypeDirect peer
Description

Early-stage biotech focused on developing therapeutics targeting the metastatic cascade. Highly comparable to Mestastop in scientific focus (metastasis biology), stage, and small-team operating model.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights5 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles2 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds3 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors5 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Mestastop Solutions

Oncology Drug Discoverymestastop.com

Mestastop Solutions is a Bengaluru-based clinical-stage biotech that uses three proprietary platforms (METAssay, METSCAN, METVivo) to identify and block metastasis-causing cancer cells, advancing two repurposed drugs into a Phase II colorectal cancer trial.

What Mestastop Solutions does

Mestastop Solutions is a Bengaluru-based, privately held biotech startup founded in 2018 that focuses on cancer metastasis — the spread of cancer cells from a primary tumor to secondary organs, which is a leading cause of cancer-related death. The company develops proprietary in vitro, in vivo, and patient ex-vivo platforms to address both metastasis drug discovery and predictive diagnostics. Its core work centers on identifying and blocking cancer cells capable of spreading, using two repurposed drugs to target metastasis in colorectal cancer patients in a planned Phase II clinical trial.

Mestastop's technology stack comprises three integrated proprietary tools — METAssay, METSCAN, and METVivo — that collectively recreate and analyze a 30-step metastasis process to surface specific cells capable of disseminating to secondary organs. The company has secured regulatory approval to launch a Phase II trial enrolling at least 60 post-surgery colorectal cancer patients in a two-year treatment regimen, with results expected in approximately three years. Cumulative disclosed funding across three rounds (2020–2023) is approximately $714,000, with backers including Mumbai Angels, IIMA Ventures, IKP Knowledge Park, 92 Angels, and Malpani Ventures. The company is co-founded by Debabani Roy Chowdhury and Arnab Roy Chowdhury.

The business model is pre-commercial: Mestastop is a clinical-stage biotech with no disclosed pricing, no paying customers, and no product revenue. Its go-to-market motion is enterprise-field-sales and regulatory-driven, dependent on clinical trial execution, future pharma partnerships, or licensing of its repurposed-drug assets and diagnostic platforms. Geographic footprint is currently limited to Bengaluru, India, with 11–50 employees and no subsidiaries or institutional parent identified in the data.

Mestastop Solutions firmographics

Firmographics
Name
Mestastop Solutions
Website
https://mestastop.com
Company type
Private
Founded year
2018
Operating status
Operating
Headcount range
11–50 employees
Short description
Mestastop Solutions is a Bengaluru-based clinical-stage biotech that uses three proprietary platforms (METAssay, METSCAN, METVivo) to identify and block metastasis-causing cancer cells, advancing two repurposed drugs into a Phase II colorectal cancer trial.
Ownership category
akta.pro rank

Mestastop Solutions industry classification

Industry
Product category
Oncology Drug Discovery
NAICS
In-Vitro Diagnostic Substance Manufacturing (325413), Medical and Diagnostic Laboratories (62151)
SIC
In Vitro & In Vivo Diagnostic Substances (2835), Services-Commercial Physical & Biological Research (8731)
akta.pro industry
PRIMARYHLAAALAE
Oncology Diagnostics (tumor profiling, MRD, liquid biopsy)
SECONDARYHLAIALAE
Clinical Development (Phase I–III Trial Design & Execution)
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Research and Development
SECONDARYHLAKAFAB
Medical Oncology

Keywords

  • Cancer metastasis research
  • Drug discovery platforms
  • Predictive diagnostics
  • In vitro assays
  • Clinical trials

Where Mestastop Solutions is headquartered

Location

Headquarters

HQ city
Marlton
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Mestastop Solutions business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Technology or R&D, Operations, Marketing or Sales, Others

Go-to-market motion1 record

Mestastop Solutions product offering

Product offering

Core offering

Mestastop Solutions develops proprietary in vitro, in vivo, and patient ex-vivo platforms that recreate and analyze the 30-step metastasis process to identify and block cancer cells capable of spreading to secondary organs. The company is preparing a Phase II clinical trial with two repurposed drugs targeting metastasis in post-surgery colorectal cancer patients, with plans to enroll at least 60 patients in a two-year treatment regimen.

Product overview

Mestastop Solutions offers a unified platform comprised of three integrated proprietary tools — METAssay, METSCAN, and METVivo — that collectively recreate and analyze the 30-step metastasis process to identify and block specific cancer cells capable of spreading to secondary organs. The company is developing two repurposed drugs for a Phase II clinical trial targeting metastasis in colorectal cancer patients.

Differentiator

Problem solved

Functional benefit

Products and services

  • METAssay One of three integrated proprietary tools that recreates and analyzes the metastasis process to identify cancer cells capable of spreading to secondary organs; part of Mestastop's platform for metastasis drug discovery and predictive diagnostics.
  • METSCAN One of three integrated proprietary tools that recreates and analyzes the metastasis process to identify cancer cells capable of spreading to secondary organs; part of Mestastop's platform for metastasis drug discovery and predictive diagnostics.
  • METVivo One of three integrated proprietary tools that recreates and analyzes the metastasis process to identify cancer cells capable of spreading to secondary organs; part of Mestastop's platform for metastasis drug discovery and predictive diagnostics.

Companies that use Mestastop Solutions

Customer profile

Segments1 record

Ideal customer profiles2 records

Mestastop Solutions technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

Mestastop Solutions partnerships and signals

Strategic signal

Scale indicators3 records

Recent moves5 records

Expansion highlights5 records

Mestastop Solutions competitors and assessment

Company assessment

Direct peers

  • Hummingbird Bioscience: Precision oncology biotech using proprietary platforms to discover and develop antibody and small-molecule therapeutics against high-value cancer targets. Comparable in platform-driven discovery approach and clinical-stage positioning.
  • Lantern Pharma: AI-driven oncology drug development company with a focus on repurposed and accelerated drug development programs, including in metastatic indications. Highly comparable in its use of repurposed drugs and platform-enabled oncology development.
  • Accutar Biotech: AI- and structure-based drug discovery company focused on oncology, using computational platforms to identify novel candidates. Comparable in platform-driven oncology drug discovery, although at a more advanced clinical stage.
  • Inzen Therapeutics: Early-stage biotech focused on developing therapeutics targeting the metastatic cascade. Highly comparable to Mestastop in scientific focus (metastasis biology), stage, and small-team operating model.

Broad incumbents

  • Guardant Health: Established oncology precision medicine company offering liquid biopsy and molecular diagnostics to identify and monitor cancer, including metastatic disease. A broad incumbent in cancer diagnostics that validates the market Mestastop's predictive diagnostics platform targets.
  • Tempus AI: AI-enabled precision medicine company with extensive oncology data, diagnostics, and drug-discovery capabilities. A broad incumbent in oncology data and diagnostics that contextualizes Mestastop's platform approach at scale.
  • Foundation Medicine: Major oncology molecular diagnostics company (a Roche subsidiary) providing comprehensive genomic profiling of tumors to inform cancer treatment. A broad incumbent whose cancer-profiling capabilities overlap with Mestastop's predictive diagnostics positioning.

Emerging players

  • SEngine Precision Medicine: Functional diagnostics company that uses patient-derived tumor cells to test drug sensitivity and guide oncology treatment selection. Comparable in patient ex-vivo testing methodology and cancer-drug matching approach.
  • Notable Labs: Functional precision medicine platform that tests cancer drugs (including repurposed drugs) against patient-derived cancer cells to predict response. Comparable in combining ex-vivo patient-cell testing with drug repurposing in oncology.
  • Repurpose.AI: AI-driven drug repurposing platform with applications across oncology. Comparable through the shared repurposed-drug development model targeting cancer indications.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat3 records

Key risks5 records

Key highlights5 records

Customer concentration

Mestastop Solutions social profiles

Digital presence

Mestastop Solutions financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Mestastop Solutions leadership team

Management profile

Number of profiles

Profiles2 records

Mestastop Solutions funding detail

Funding detail

Funding overview

Funding rounds3 records

Investors5 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Mestastop Solutions M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Mestastop Solutions

What does Mestastop Solutions do?

Mestastop Solutions develops proprietary in vitro, in vivo, and patient ex-vivo platforms that recreate and analyze the 30-step metastasis process to identify and block cancer cells capable of spreading to secondary organs. The company is preparing a Phase II clinical trial with two repurposed drugs targeting metastasis in post-surgery colorectal cancer patients, with plans to enroll at least 60 patients in a two-year treatment regimen.

Is Mestastop Solutions a public or private company?

Mestastop Solutions is a private company. It is classified as venture growth investor backed and is currently operating.

When was Mestastop Solutions founded?

Mestastop Solutions was founded in 2018. It employs 11 to 50 people.

Where is Mestastop Solutions based?

Mestastop Solutions is headquartered in Marlton, United States, in the North America region.

Who are Mestastop Solutions's main competitors?

Direct peers on record are Hummingbird Bioscience, Lantern Pharma, Accutar Biotech and Inzen Therapeutics. Broad incumbents are Guardant Health, Tempus AI and Foundation Medicine. Emerging players are SEngine Precision Medicine, Notable Labs and Repurpose.AI.

Does Mestastop Solutions have an API?

No public API is recorded for Mestastop Solutions.

What industry is Mestastop Solutions in?

Mestastop Solutions's product category is Oncology Drug Discovery. Its primary akta.pro industry code is HLAAALAE, Oncology Diagnostics (tumor profiling, MRD, liquid biopsy), with a secondary code of HLAIALAE, Clinical Development (Phase I–III Trial Design & Execution). Its NAICS code is 325413 and its SIC code is 2835.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
The Times of IndiaMestastop raises $500k to further its cancer drug discovery - The Economic TimesBiotechnology startup Mestastop Solutions has raised $500k (Rs 4.5 crore) in a Pre Series A funding round led by 92 Angels and Malpani Ventures. The company plans to utilize the capital to generate proof-of-concept data for small molecules targeting cancer metastasis and advance drug repurposing efforts. This follows a previous seed funding of Rs 2 crore secured in 2021 from IIM Ahmedabad’s CIIE, IKP, and angel investors.EntrackrMestastop raises $500K in pre-Series A roundMestastop Solutions raised $500,000 in a pre-Series A funding round led by 92 Angels and Malpani Ventures. The company intends to use the capital for proof of concept data generation, drug repurposing efforts, and strategic business development activities related to its cancer metastasis platform.Business StandardMestastop Solutions raises Rs 1.3 cr in seed round led by CIIE.COMestastop Solutions raised Rs 1.3 crore in a seed round led by CIIE.CO, with participation from IKP Knowledge Park and Angels. The Bengaluru-based biotech startup will use the funds to scale its AI-based METSCAN platform for cancer cell characterization and validate proof of concept via animal models. The company has filed one international patent and is working on a provisional patent.EntrackrBiotech startup Mestastop Solutions raises seed fundMestastop Solutions raised Rs 1.3 crore ($173K) in a seed round led by CIIE.CO, with participation from IKP Knowledge Park and angels. The Bengaluru-based biotech startup will use the funds to scale its AI-based METSCAN platform for cancer cell characterization and run proof-of-concept animal studies for drug discovery.IndiaWeb2Biotech Startup Mestastop Solutions Raises 1.3 Cr from CIIE.CO to Map the Anatomy of Cancer Using Deep-dive AnalysisBengaluru-based biotech startup Mestastop Solutions has raised INR 1.3 Crores in seed funding led by CIIE.CO to scale its AI-based platform, METSCAN, for cancer metastasis diagnostics and drug discovery. The funds will support proof-of-concept animal model studies and the validation of proprietary platforms against patient tumor samples.